Abstract
Selective inhibitors of the Src family of protein tyrosine kinases have been developed as therapeutic agents for human tumors, some of which are now in various stages of clinical trial. In this review, recently described novel small molecule ATP-competitive Src inhibitors are discussed, with an emphasis on their potential use as therapeutic inhibitors for advanced-stage malignancies.
Keywords: Src family kinase, Inhibitors, Adenocarcinoma
Mini-Reviews in Medicinal Chemistry
Title: Src Inhibitors as Potential Therapeutic Agents for Human Cancers
Volume: 6 Issue: 6
Author(s): Jose G. Trevino, Justin M. Summy and Gary E. Gallick
Affiliation:
Keywords: Src family kinase, Inhibitors, Adenocarcinoma
Abstract: Selective inhibitors of the Src family of protein tyrosine kinases have been developed as therapeutic agents for human tumors, some of which are now in various stages of clinical trial. In this review, recently described novel small molecule ATP-competitive Src inhibitors are discussed, with an emphasis on their potential use as therapeutic inhibitors for advanced-stage malignancies.
Export Options
About this article
Cite this article as:
Trevino G. Jose, Summy M. Justin and Gallick E. Gary, Src Inhibitors as Potential Therapeutic Agents for Human Cancers, Mini-Reviews in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/138955706777435724
DOI https://dx.doi.org/10.2174/138955706777435724 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Oncotargets in Different Renal Cancer Subtypes
Current Drug Targets Chemokines and Defensins as HIV Suppressive Factors: An Evolving Story
Current Pharmaceutical Design Drug Metabolism and Pharmacokinetics of Nanodrugs from Chinese Medicines and Natural Products
Current Drug Metabolism The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Current Medicinal Chemistry Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Epigenetic MicroRNA Regulation of Multiple Chromatin Functions: A Perspective in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Male Fertility-Implications of Anticancer Treatment and Strategies to Mitigate Gonadotoxicity
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery Hormone Responsive Breast Cancer and BRCA1 Mutation: Mechanism, Regulation and Iron-mediated Effects
Current Pharmaceutical Biotechnology Prediction of Cancer Rescue p53 Mutants In Silico Using Naïve Bayes Learning Methodology
Protein & Peptide Letters Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry Role of Infrared Spectroscopy in Medicinal Plants Research in Pakistan
Current Bioactive Compounds Recent Advances in T Cell Adoptive Immunotherapy of Cancer
Current Cancer Therapy Reviews Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design